Merus (MRUS) Stock Price, News & Analysis

Company Overview

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development. Key programs are being evaluated in solid tumors and hematological malignancies, with a focus on innovative mechanisms of action that harness T cell redirection, immune checkpoint modulation and co-stimulatory pathways. In addition to its internal development efforts, Merus collaborates with strategic partners to advance select programs and expand its therapeutic reach.

Headquartered in Utrecht, the Netherlands, Merus maintains operations in both Europe and the United States, supporting global clinical trials and regulatory activities. The company completed its initial public offering on the Nasdaq stock market in October 2018, and its research sites extend from the Dutch biotech hub to a dedicated U.S. presence in Boston’s ecosystem.

Merus is led by a management team with extensive experience in oncology drug development and commercialization. Under the leadership of Chief Executive Officer Ton Logtenberg, the company continues to advance its bispecific antibody platform, aiming to deliver transformative treatments for patients with unmet medical needs.

Key Stats

• Today's Range: $87.14 to $96.86
• 50-Day Range: $90.00 to $97.01
• 52-Week Range: $37.92 to $97.14
• Volume: 2.73 million shs
• Average Volume: 1.51 million shs
• Market Capitalization: $6.83 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $95.93
• Consensus Rating: Hold

Merus Stock Analysis - MarketRank™

Merus scored higher than 3% of companies evaluated by MarketBeat, and ranked 862nd out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Hold

Consensus Rating

Merus has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 13 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Merus is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Merus has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merus is -16.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merus is -16.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Merus has a P/B Ratio of 9.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MRUS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Merus does not currently pay a dividend.

Dividend Growth

Merus does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Merus this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Merus insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.70% of the stock of Merus is held by insiders.

Percentage Held by Institutions

96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2025
• Today: 6/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRUS
• CIK: 1651311
• Web: www.merus.nl
• Phone: (130) 253-8800
• Fax: N/A
• Employees: 37
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Merus: $95.93
• High Price Target: $97.00
• Low Price Target: $90.00
• Potential Upside/Downside: +6.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$215.33 million
• Net Margins: -673.31%
• Pretax Margin: -653.35%
• Return on Equity: -52.99%
• Return on Assets: -44.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.97
• Quick Ratio: 7.97

Sales & Book Value

• Annual Sales: $36.13 million
• Price / Sales: 188.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.46 per share
• Price / Book: 9.51

Miscellaneous

• Outstanding Shares: 75,850,000
• Free Float: 73,041,000
• Market Cap: $6.83 billion
• Optionable: Optionable
• Beta: 1.06